BioSpace News Archive

Biocom CaliforniaBiocom CaliforniaBiocom CaliforniaBiocom California, the association representing the life science industry of California, issued the following statement in response to the White House’s support of a proposal to waive intellectual property rights for COVID-19 vaccines.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction, today announced the pricing of its initial public offering of 3,000,000 shares of common stock at a public offering price of $7.00 per share.

ChemoCentryx, Inc., announced the outcome of the U.S. Food and Drug Administration Arthritis Advisory Committee on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody -associated vasculitis.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2021 after the market close on Wednesday, May 12, 2021.

F-star Therapeutics, Inc. (Nasdaq: FSTX) (the “Company” or “F-star”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has commenced an underwritten public offering of its common stock

Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ:89140), said it has secured a 50% stake in RosVivo Therapeutics Inc., a U.S. new drug developer, as its first investment destination.

Vivos Therapeutics, Inc., a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea, announced the pricing of its underwritten follow-on public offering of 4,000,000 shares of its common stock at a public offering price of $6.00 per share.

Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, announced the pricing of its initial public offering of 8,825,000 shares of common stock at a price to the public of $17.00 per share.

Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced results from parallel laboratory studies conducted in collaboration with academic and government partners in Switzerland and the United States.

The assisted living market is predicted to display noteworthy growth in the years ahead driven by a number of factors.